

Screening and identification of Chronic Kidney Disease for general practitioners

Swiss Society of Nephrology

1

CKD in Switzerland

- Due to the aging of the Swiss population and growing prevalence of diseases, which harm the kidney (e.g. diabetes mellitus, arterial hypertension), chronic kidney disease (CKD) prevalence is increasing.¹ Data suggests that 1 in 10 adults in Switzerland is affected by CKD.²
- It is important to prevent CKD, detect CKD early and to optimally manage patients with CKD.
- This goal can only be achieved in a collaborative effort involving general practitioners and specialists.

2

Definition of CKD

- CKD is defined as «abnormalities of kidney structure or function, present for >3 months with implications for health».³
- CKD is classified based on cause, eGFR, and albuminuria category (Figure 1).

3

Detection of CKD

- Treatments are available to prevent CKD progression, reduce its complications (such as CV disease) and thus significantly reduce CKD morbidity and mortality.
- However, because CKD is often asymptomatic, it is vastly underdiagnosed. 9 out of 10 people with CKD are unaware that they are affected.⁴ Therefore, individuals with a high risk for CKD should be screened.
- Patients with arterial hypertension, diabetes mellitus, and cardiovascular disease should be screened for CKD at least once annually.^{3,5,6}
- Other populations at risk should also be screened on a regular basis (Figure 2).
- The screening approach consists of both determination of eGFR (by measurement of creatinine, cystatin C, or both) and quantification of albuminuria.^{3,5}

CKD

is classified based on:

- Cause (C)
- eGFR (G)
- Albuminuria (A)

- Low risk
can reflect CKD with normal eGFR and albumin-to-creatinine ratio only in the presence of other markers of kidney damage)
- Moderately increased risk
- Moderately to greatly increased risk
- High risk
- Very high risk

				Albuminuria categories Description and range		
				A1	A2	A3
				Normal to mildly increased	Moderately increased	Severely increased
				<30 mg/g <3 mg/mmol	30-300 mg/g 3-30 mg/mmol	>300 mg/g >30 mg/mmol
eGFR categories (ml/min/1.73m ²) Description and range	G1	Normal to high	≥90	1 if CKD	Treat 1	Refer 2
	G2	Mildly decreased	60-89	1 if CKD	Treat 1	Refer 2
	G3a	Mildly to moderately decreased	45-59	Treat 1	Treat 2	Refer 3
	G3b	Moderately to severely decreased	30-44	Treat 2	Treat 3	Refer 3
	G4	Severely decreased	15-29	Refer 3	Refer 3	Refer 4+
	G5	Kidney failure	≤15	Refer 4+	Refer 4+	Refer 4+

Figure 1 - Staging, classification and risk stratification of CKD according to KDIGO. The numbers in the boxes are a guide to the frequency of visits (number of times per year). The GFR and albuminuria grid depicts the risk of progression, morbidity, and mortality by color, from best to worst (green, yellow, orange, red, dark red). (ADA Standards of Medical Care in Diabetes 2021 - Abridged for Primary Care Providers).^{3,7}




Figure 2 - Suggested algorithm how to screen, stratify, and manage individuals at risk of or with CKD and when to refer to a nephrologist (AKI: acute kidney injury, SGLT2i sodium-glucose co-transporter 2 inhibitor, GLP1-RA: glucagon-like peptide 1 receptor agonist, CKD: chronic kidney disease, RAAS renin-angiotensin-aldosterone system, ACR: urine albumin-creatinine ratio, eGFR estimated glomerular filtration rate, K⁺: potassium, HIV: human immunodeficiency virus, SLE: systemic lupus erythematosus).^{3,6,8}

Authors: Harald Seeger, Sophie de Seigneux, Pietro Cippà, for the Swiss Society of Nephrology.

References: 1. Xie Y, et al., *Kidney Int.* 2018;94(3):567-81. 2. Ognja VF, et al., *Swiss Med Wkly.* 2016;146:w14313. 3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. *Kidney Int* 2013;3(Suppl):1-150. 4. GBD Chronic Kidney Disease Collaboration. *Lancet*, 2020;395(10225):709-733. 5. Shlipak MG, et al., for Conference Participants, *Kidney International* (2020). doi: <https://doi.org/10.1016/j.kint.2020.10.012>. 6. SGED: GDMD Kriterien für ein „gutes“ Disease Management Diabetes in der Grundversorgung. https://www.sgedssed.ch/fileadmin/user_upload/6_Diabetologie/64_Ressourcen_Hausarzt/Diabetes_Kriterien_2017_SGED_def.pdf. 7. American Diabetes Association. *Diabetes Care*, 2021 Jan;44: 10.2337/dc21-S005. 8. Delanaye P, et al. *JASN* 30: 1785-1805, 2019.

The layout of this booklet was kindly supported by an unrestricted educational grant from AstraZeneca.